NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Collaborating Centre for Mental Health (UK). Challenging Behaviour and Learning Disabilities: Prevention and Interventions for People with Learning Disabilities Whose Behaviour Challenges. London: National Institute for Health and Care Excellence (NICE); 2015 May. (NICE Guideline, No. 11.)
Challenging Behaviour and Learning Disabilities: Prevention and Interventions for People with Learning Disabilities Whose Behaviour Challenges.
Show detailsO.1. Risk markers associated with the development of behaviour that challenges
O.1.1. Auditory impairment
Table O.1. Auditory impairment versus no auditory impairment as a risk factor for challenging behaviour (PDF, 196K)
O.2. Autism diagnosis
Table O.2. Autism diagnosis versus no autism diagnosis as a risk factor for challenging behaviour (PDF, 198K)
O.2.1. Degree of learning disability
O.2.2. Expressive communication difficulties
O.2.4. Receptive communication difficulties
O.2.5. Gender
Table O.6. Male gender versus female gender as a risk factor for challenging behaviour (PDF, 273K)
O.2.6. Mental health needs
Table O.7. Mental health needs versus no mental health needs as a risk factor for challenging behaviour (PDF, 199K)
O.2.7. Mobility impairment
Table O.8. Mobility impairment versus no mobility impairment as a risk factor for challenging behaviour (PDF, 189K)
O.2.8. Visual impairment
Table O.9. Visual impairment versus no visual impairment as a risk factor for challenging behaviour (PDF, 189K)
O.3. Interventions aimed at the prevention of behaviour that challenges
O.3.1. Educational intervention versus attention control
O.3.2. Home-based EBI versus centre-based EBI
Table O.11. Home-based Building Blocks programme versus centre-based Building Blocks programme (PDF, 253K)
O.3.3. EIBI versus parent training
Table O.12. EIBI (UCLA model) versus parent training (PDF, 260K)
O.3.4. High supervision EIBI versus low supervision EIBI
O.3.5. Parent training versus any control
Table O.14. Parent training (plus centre based EBI) versus treatment as usual (centre-based EBI) (PDF, 262K)
O.4. Interventions aimed at reducing health risks and increasing understanding of physical illness in relation to the prevention or management of behaviour that challenges
O.4.1. Hand-held health record versus treatment as usual
Table O.15. Advocacy Skills Kit Diary or Personal Health Profile versus treatment as usual (PDF, 232K)
O.4.2. Annual health check versus treatment as usual
Table O.16. Comprehensive Health Assessment Program versus treatment as usual (PDF, 229K)
O.4.3. Annual health check versus hand-held health record
Table O.17. Comprehensive Health Assessment Program versus Advocacy Skills Kit Diary (PDF, 210K)
O.4.4. Annual health check and hand-held health record versus treatment as usual
Table O.18. Comprehensive Health Assessment Program and Advocacy Skills Kit Diary versus treatment as usual (PDF, 203K)
O.5. Environmental change interventions aimed at reducing and managing behaviour that challenges
O.5.1. Sensory intervention versus any control
Table O.19. Multisensory room or vibroacoustic chair versus any control (PDF, 284K)
O.5.2. Structured activity versus unstructured activity
Table O.20. Special Olympics Sports Skill Instructional Program versus free play (PDF, 248K)
O.6. Parent training interventions aimed at reducing and managing behaviour that challenges
O.6.1. Parent training versus any control
Table O.21. Parent training versus any control (PDF, 270K)
O.6.2. Individual parent training versus group parent training
Table O.22. Individual parent training versus group parent training (PDF, 257K)
O.6.3. Parent training plus optimism training versus parent training alone
Table O.23. Parent training plus optimism training versus parent training alone (PDF, 252K)
O.6.4. Enhanced parent training versus standard parent training
Table O.24. Enhanced parent training versus standard parent training (PDF, 275K)
O.7. Psychosocial interventions aimed at reducing and managing behaviour that challenges
O.7.1. Cognitive behavioural interventions versus any control
Table O.25. Cognitive behaviour interventions versus any control (PDF, 273K)
O.7.2. Behavioural therapy versus any control
Table O.26. Behavioural therapy versus any control (PDF, 244K)
O.8. Sleep interventions aimed at reducing and managing behaviour that challenges
O.8.1. Sleep interventions versus any control
Table O.27. Sleep interventions versus any control (PDF, 289K)
O.8.2. Face-to-face sleep intervention versus booklet only
Table O.28. Face-to-face sleep intervention versus booklet only (PDF, 240K)
O.9. Pharmacological interventions aimed at reducing and managing behaviour that challenges
O.9.1. Risperidone versus placebo in children and young people
Table O.29. Risperidone versus placebo in children and young people (PDF, 291K)
O.9.2. Withdrawal of risperidone versus continuation of risperidone in children and young people
Table O.30. Withdrawal of risperidone versus continuation of risperidone in children and young people (PDF, 240K)
O.9.3. Aripiprazole versus placebo in children and young people
Table O.31. Aripiprazole versus placebo in children and young people (PDF, 273K)
O.9.4. Aripiprazole versus risperidone in children and young people
Table O.32. Aripiprazole versus risperidone in children and young people (PDF, 255K)
O.9.5. Withdrawal of aripiprazole versus continuation of aripiprazole in children and young people
Table O.33. Withdrawal of aripiprazole versus continuation of aripiprazole in children and young people (PDF, 256K)
O.9.6. Olanzapine versus haloperidol in children and young people
Table O.34. Olanzapine versus haloperidol in children and young people (PDF, 254K)
O.9.7. Topiramate (plus risperidone) versus placebo (plus risperidone) in children and young people
Table O.35. Topiramate (plus risperidone) versus placebo (plus risperidone) in children and young people (PDF, 254K)
O.9.8. Valproate versus placebo in children and young people
Table O.36. Topiramate (plus risperidone) versus placebo (plus risperidone) in children and young people (PDF, 269K)
O.9.9. N-acetylcysteine versus placebo in children and young people
Table O.37. N-acetylcysteine versus placebo in children and young people (PDF, 253K)
O.9.10. Ginkgo biloba (plus risperidone) versus placebo (plus risperidone) in children and young people
Table O.38. Ginkgo biloba (plus risperidone) versus placebo (plus risperidone) in children and young people (PDF, 251K)
O.9.11. Omega-3 versus placebo in children and young people
Table O.39. Omega-3 versus placebo in children and young people (PDF, 251K)
O.9.12. Piracetam (plus risperidone) versus placebo (plus risperidone) in children and young people
Table O.40. Piracetam (plus risperidone) versus placebo (plus risperidone) in children and young people (PDF, 242K)
O.9.13. Risperidone versus placebo in adults
Table O.41. Risperidone versus placebo in adults (PDF, 277K)
O.9.14. Haloperidol versus placebo in adults
Table O.42. Haloperidol versus placebo in adults (PDF, 214K)
O.9.15. Risperidone versus haloperidol in adults
Table O.43. Risperidone versus haloperidol in adults (PDF, 271K)
O.9.16. Olanzapine versus risperidone in adults
Table O.44. Olanzapine versus risperidone in adults (PDF, 256K)
O.9.17. Lithium versus placebo in adults
Table O.45. Lithium versus placebo in adults (PDF, 193K)
O.9.18. Withdrawal of zuclopenthixol versus continuation of zuclopenthixol in adults
Table O.46. Withdrawal of zuclopenthixol versus continuation of zuclopenthixol in adults (PDF, 273K)
O.9.19. Melatonin versus placebo in children and young people
Table O.47. Melatonin versus placebo in children and young people (PDF, 347K)
O.9.20. Melatonin versus cognitive behavioural therapy in children and young people
Table O.48. Melatonin versus cognitive behavioural therapy in children and young people (PDF, 263K)
O.10. Interventions aimed at improving the health and well-being of carers of people with learning disabilities
O.10.1. Cognitive behavioural interventions for family carers versus any control
Table O.49. Cognitive behavioural interventions for family carers versus any control (PDF, 282K)
O.10.2. Psychoeducational interventions for family carers versus any control
Table O.50. Psychoeducational interventions for family carers versus any control (PDF, 250K)
O.10.3. Support interventions for family carers versus any control
Table O.51. Parent advisor scheme versus treatment as usual (PDF, 241K)
O.10.4. Mindfulness interventions for paid carers versus any control
Table O.52. Mindfulness interventions for paid carers versus any control (PDF, 271K)
- Risk markers associated with the development of behaviour that challenges
- Autism diagnosis
- Interventions aimed at the prevention of behaviour that challenges
- Interventions aimed at reducing health risks and increasing understanding of physical illness in relation to the prevention or management of behaviour that challenges
- Environmental change interventions aimed at reducing and managing behaviour that challenges
- Parent training interventions aimed at reducing and managing behaviour that challenges
- Psychosocial interventions aimed at reducing and managing behaviour that challenges
- Sleep interventions aimed at reducing and managing behaviour that challenges
- Pharmacological interventions aimed at reducing and managing behaviour that challenges
- Interventions aimed at improving the health and well-being of carers of people with learning disabilities
- Clinical evidence – GRADE evidence profiles for all studies - Challenging Behavi...Clinical evidence – GRADE evidence profiles for all studies - Challenging Behaviour and Learning Disabilities
Your browsing activity is empty.
Activity recording is turned off.
See more...